Insights - KaloBios Pharmaceuticals (KBIO) slid 16% to $1.61 in after hours trading on the news that Sanofi Pasteur, the vaccines division of French pharma giant Sanofi, … Continue Reading
Read NowInsights - The story of the week was Puma Biotechnology’s (PBYI) unexpected success in the phase 3 ExteNET trial, which sent the stock soaring 200% in after hours trading on Tuesday … Continue Reading
Read NowInsights - A second late-stage study of Incyte’s (INCY) Jakafi (ruxolitinib) in polycythemia vera (PV) failed on Wednesday, though the company says the study isn’t necessary for FDA approval. RELIEF was … Continue Reading
Read NowInsights - Biogen Idec (BIIB) trounced analyst estimates on Wednesday, a beat led by $700 million in Tecfidera sales during the quarter that topped consensus estimates for $561 million. Ex-U.S., the … Continue Reading
Read NowInsights - Puma Biotechnology (PUMA) shares ripped higher by 200% in after-hours trading on Tuesday with positive results from a late-stage trial of Puma’s experimental breast cancer drug, neratinib. The ExteNET … Continue Reading
Read NowInsights - With Sandoz deal, Anacor (ANAC) investors can get a little more comfortable with the upcoming commercial launch.
Read NowInsights - Prana Biotech (PRAN) said on Thursday that after further analysis of a failed Alzheimer’s study, the company will likely move forward with lead drug candidate PBT2 in … Continue Reading
Read Now
